• Mashup Score: 0

    Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.

    Tweet Tweets with this article
    • In this episode of #OncLiveOnAir, Dr Mirza discusses the @US_FDA approval of #dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. #gyncsm https://t.co/tvSDHDkCHx https://t.co/lwpoXzglJ3

  • Mashup Score: 1

    Data from a pair of single-arm clinical trials will be sufficient to illustrate the benefits and risks of dostarlimab-gxly for a subgroup of patients with rectal cancer, according to the FDA’s Oncologic Drugs Advisory Committee. The panel voted 8-5 that the studies, set to enroll a total of 130 patients, would provide adequate data on use of the anti-PD-1 monoclonal antibody in the

    Tweet Tweets with this article
    • ODAC: Single-arm trial data will suffice for dostarlimab in rectal cancer subgroup. https://t.co/YIFaZM0TaV #dostarlimab #rectalcancer #Jemperli @GSK